Second-Line Treatment for HR+, HER2- Metastatic Breast Cancer

With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the importance of tailoring treatment for every patient.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.

Oral drugs in the HR-positive, HER2-negative metastatic breast cancer space put a focus on clear patient-provider communication about adherence and adverse events.

Testing for ESR1 mutations is essential after ER-positive HER2-negative breast cancer progressed.

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or metastatic breast cancer

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.